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Endothelin-1 stimulates cytosolic phospholipase A2 activity and gene
expression in rat glomerular mesanglal cells. Endothelin-i (ET-1) stimulates
vascular smooth muscle and mesangial cells to release prostaglandin E2
(PGE2), which can attenuate the vasoconstrictor and mitogenic effects of this
peptide. Phospholipase A2 (PLA2)-mediated release of arachidonic acid from
the sn-2 position of membrane phospholipids is thought to be one of the
rate-limiting steps in prostaglandin (PG) synthesis. We evaluated the role of
ET-1 to regulate gene expression, protein synthesis and enzymatic activity of
cytosolic PLA2 (cPLA2), an intracellular form of the PLA2 enzyme family, in
cultured rat mesangial cells using both acute and chronic incubation proto-
cols. Acute ET-1-induced stimulation of cPLA2 activity was maximal after 10
minutes (181.1 6.84% of control), persisted for 40 minutes and did not
require new protein synthesis. Heparin, a potent inhibitor of intracellular
Ca2 increase as well as mitogen-activated protein (MAP) kinase activation
and cell proliferation, did not affect the rapid cPLA2 stimulation by ET-1.
Chronic incubation of glomerular mesangial cells with FT-i (ito 24 hr) led
to time- and dose-dependent increases in cPLA2 mRNA expression which
was maximal after six hours, persisted up to 24 hours and which was
accompanied by both cPLA2 protein formation, as assessed by Western
analysis, as well as by stimulation of enzymatic activity. Inhibition of protein
synthesis by cycloheximide increased basal cPL.A2 mRNA accumulation in
quiescent mesangial cells, and the combination of FT-i and cycloheximide
resulted in a greater induction of cPLA2 gene expression when compared to
ET-1 alone. Actinomycin D treatment blocked the effect of ET-1 on cPLA2
mRNA accumulation. Herbimycin A, an inhibitor of cellular protein tyrosine
kinases, abrogated the FT-i-induced cPLA2 gene expression, while protein
kinase C (P1(C) inhibitors (Calphostin, Sangivamycin) only slightly reduced
cPLA2 mRNA, We thus conclude that ET-1 is able to stimulate cPLA2 in a
biphasic manner: Acute stimulation starts after five minutes and does not
require de novo protein synthesis, while long-term activation after three hours
is most likely linked to cPLA2 gene expression via a cellular tyrosine kinase
pathway. FT-i-mediated acute and chronic stimulation of cPLA2 could serve
as an autocrine and/or paracrine negative regulator for vasoconstrictive and
mitogenic effects of ET-1.
Endothelin-1 (ET-1) is a vasoactive and mitogenic peptide, which
has diverse effects on kidney function and mesangial cell biology [1].
Nanomolar or higher concentrations of this peptide induce potent
and long lasting vasoconstrictor effects in most vessels of the cardio-
vascular system. Bolus administration of ET-1, however, leads to a
biphasic blood pressure response consisting of an initial, transient
depressor response, followed by a marked and sustained pressor
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phase [2]. Depending on the species and vascular beds studied, the
early depressor response is due to an endothelin mediated release of
vasodilatory prostaglandins (PG) and/or endothelium-derived nitric
oxide [3]. Pretreatment with cyclooxygenase inhibitors potentiates
the pressor response to endothelin (ET) in pithed rats, indicating
that vasodilatory prostaglandins are limiting the pressor activity of
ET [4].
In the kidney, intravenous and intra-arterial infusion of ET
leads to an intense, dose-dependent renal vasoconstriction accom-
panied by substantial reductions of renal blood flow (RBF),
glomerular filtration rate (GFR) and urine flow rate as well as an
increase of renal vascular resistance [5, 6]. The reduction of GFR
seen at higher ET doses can be caused by the contraction of
intraglomerular mesangial cells, which seem to reduce the gb-
merular capillary surface area available for ultrafiltration, thereby
leading to a dramatic fall in the glomerular ultrafiltration coeffi-
cient (Kf) [7]. Similar to the systemic response, transient renal
vasodilation often precedes vasoconstriction induced by ET [3].
Inhibition of PG synthesis partially prevents the early renal
vasodilatation induced by ET, thereby potentiating the decline in
RBF and GFR [8]. Renal venous and arterial as well as urinary
6-ketoprostaglandin F1 increase after ET infusion [8]. Thus, the
renal hemodynamic effects of ET are significantly influenced by its
ability to enhance production of vasodilatory PG.
Prostaglandin E2 (POE2) and 12 (PGI2) formation are the result
of similar sequential enzymatic activities: phospholipase A2
(PLA2), prostaglandin endoperoxide synthase (PGHS) and PGE2
or PGI2 synthase [9]. The rate limiting step in PG synthesis seems
to be the phospholipase A2 (PLA2)-mediated release of arachi-
donic acid from the sn-2 position of membrane phospholipids
[reviewed in 10]. Phospholipases A2 comprise a family of enzymes
and can be subdivided into secretory and intracellular forms [10,
11]. One group contains different secretory phospholipases A2
(5PLA2), which have molecular masses in the range of about 14
kDa with seven disulfide bonds, depend upon millimolar concen-
trations of calcium for maximal activity and do not demonstrate
preference for the fatty acid present in the sn-2 position of
phospholipids. Another form, an intracellular, high-molecular
weight cytosolic phospholipase A2 (cPLA2), which is hormonally
regulated, dithiothreitol-insensitive and which depends upon mi-
cromolar concentrations of calcium for maximal activity, has been
identified in glomerular mesangial cells and the human monocyte
cell line U937 [12—14] and has been purified from pig spleen,
bovine lung and bovine kidney [15]. Furthermore, a eDNA
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encoding a 85.2 kDa PLA2 protein, which lacks any identity with
sPLA2 cDNA's, has been cloned recently [16, 17].
Although it is well known that cPLA2 can be rapidly activated by
different agonists in glomerular mesangial cells [12, 18—20], only
indirect evidence exists for a role of cPLA2 in ET-1-induced postre-
ceptor signaling. In mesangial and endothelial cells, for example,
ET-1 has been reported to induce release of both PGE2 and stable
metabolites of PG!2 or TXA2 [21—24]. An ET-1-stimulated [3H]arac-
hidonic acid release has been shown in vascular smooth muscle cells
[25, 26], glomerular mesangial cells [21] and, more recently, in
Chinese hamster ovary (CHO) cells stably expressing the bovine ETA
or the rat ETB receptor [27}. Beyond that, using CHO cells stably
expressing either the human ETA or ETB receptor, we were able to
directly measure an ET-1-stimulated rapid increase in cPLA2 activity
through both ET receptors [28].
Compared to the acute stimulation of cPLA2, less is known
about the regulation of cPLA2 gene expression. To date agonist-
induced cPLA2 gene expression has only been reported for
cytokines [20, 29, 30], EGF [31], macrophage colony-stimulating
factor [32] and PMA [31], but not for G-protein-coupled agonists.
For these reasons we have investigated the ET-1-induced
activation of cPLA2 in mesangial cells as well as the underlying
mechanisms of its acute and chronic regulation. We now report
that ET-1 rapidly increases cPLA2 activity without de novo protein
synthesis. Long-term incubations in the presence of ET-1, how-
ever, induce cPLA2 mRNA expression, which is accompanied by
an increase in protein mass as well as enzymatic activity. This
ET-1 stimulated cPLA2 mRNA expression occurs via tyrosine
phosphorylation signaling cascades.
Methods
Mesangial cell culture
Glomerular mesangial cells (GMC) from male Sprague-Dawley
rats were isolated and characterized as reported previously [33].
Cells were maintained in RPMI 1640 medium supplemented with
17% fetal bovine serum (FBS), 100 U/mi penicillin, 100 tg/ml
streptomycin, 5 gJml each of insulin (I) and transferrin (T), and
5 ng/ml of selenite (S) at 37°C in a 5% CO2 incubator. GMC in
passages 10 to 20 were employed in this study.
Experimental protocols
For short-term incubations (time points 5, 10, 20 and 40 mm),
confluent GMC (passage 10-20) were placed in FBS- and ITS-free
RPMI 1640 for two hours prior to the experiment. ET-1 or carrier
were then added directly to the media. For long-term incubations
(1, 3, 6, 9, 12 and 24 hr) GMC were made quiescent for 24 hours
in FBS- and ITS-free RPMI 1640. Thereafter, media were
changed and agonists or carrier were added to this fresh FBS- and
ITS-free RPMI 1640. After various times of incubation, cells were
used for measurements of PLA2 activity as well as for Western
blot or Northern blot analysis.
PIA2 activity assay
PLA2 activity was assayed according to a method recently
published elsewhere [12, 28]. After the respective incubation
protocols GMC were rinsed three times and scraped at 4°C into a
homogenization buffer containing 50 mrvi HEPES (pH 7.4), 250
m sucrose, 1 mM EGTA, 1 mrvi EDTA, 1 j.tg/ml leupeptin, 1
g/ml pepstatin, 0.1 mivi PMSF and 1,000 kallikrein-inactivating
U/mi Trasyioi. After cells were homogenized with 25 strokes in a
tight Dounce homogenizer, nuclei and debris were removed by
centrifugation at 500 x g for five minutes. The low speed
supernates were spun at 200,000 X g for one hour in a Beckman
ultracentrifuge with a Ti-70. 1 rotor. The high-speed supernates
from control and agonist-stimulated cells were matched for
protein concentration by appropriate dilution and assayed for
cPLA2 activity using [14Cjarachidonyl-phosphatidylcholine as a
substrate. The radiolabeled phospholipid substrates were dried
down under argon and dissolved in dimethyl sulfoxide. Two
microliters of substrate (final concentration, 15 M) were pipetted
into an Eppendorf microcentrifuge tube. Reactions were initiated
by the addition of 34 pA of cell extracts as well as by addition of an
assay buffer containing 5.0 mivi CaCl2 and 50 mrvi HEPES, pH 7.5
(final concentrations); the reaction mixture was incubated for 30
minutes at 37°C. The reaction was terminated by the addition of
40 pA of 2% acetic acid in ethanol, containing 10 tg unlabeled
arachidonic acid. Release of free fatty acid was analyzed using
silica gel thin layer chromatography plates (LK5D, Whatman).
Fifty microliters of the reaction mixture and appropriate stan-
dards were spotted onto heat-activated plates and developed in
the organic phase of ethyl acetate:isooctane:H20:acetic acid,
55:75:100:8. Lipids were visualized by 12 staining. The free arachi-
donic acid band was scraped and quantified by scintillation
counting. Each assay was performed in triplicate. Blank samples
contained no cell extract. cPIA2 activity was expressed as % of
control.
Western blot analysis
Total mesangial cell lysates were separated on SDS-10%PAGE,
transferred to nitrocellulose paper, and blotted with a specific
anti-cPLA2 antibody [15]. The primary antibody (1/1000-diluted
antiserum) was detected using horseradish peroxidase-conjugated
goat anti-rabbit IgG visualized by Amersham ECL system after
intensive washing of the sheets. An equal number of cells was
loaded in each lane and equal protein loading was verified by
staining blots with Ponceau solution.
RNA extraction and Northern RNA blot analysis
Total cellular RNA was isolated by the acid guanidium thiocy-
anate-phenol-chloroform procedure of Chomczynski and Sacchi
[34]. The quality of RNA was assessed by measuring the 260
nm/280 nm ratio and determining the ratio of 28S:18S rRNA (2:1)
in ethidium-stained denaturing agarose gels. For Northern anal-
ysis RNA was denatured by heating for 15 minutes at 65°C in 0.02
M 3-[N-morpholino]propanesulfonic acid, 6.6% formaldehyde,
and 50% formamide and fractionated by electrophoresis through
a 1.2% agarose gel. The RNA was transferred to nitrocellulose
and hybridized with the 2.7 kb human cPLA2 cDNA insert [16]
labeled by nick translation with [y-32P]dCTP (New England
Nuclear). After hybridization overnight the membranes were
washed twice with 2 x SSPE-0.1% SDS at 25°C for 15 minutes
and once with 0.2 X SSPE-O.1% SDS at 42°C for 10 minutes and
exposed to Fuji RX medical X-ray film at —70°C with intensit'ing
screens. After stripping each blot and exposing for 24 hours to
ensure complete removal of the probe, the filter was rehybridized
with a nick-translated glyceraldehyde phosphate dehydrogenase
(GADPH) cDNA probe. cPLA2 hybridization signals were quan-
tified by scanning densitometry and divided by the fold increase in
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GADPH mRNA from the same blot. Autoradiograms are from
representative experiments.
Materials
ET-1, leupeptin and pepstatin A were purchased from Peptide
Institute Inc. (Osaka, Japan). Trasylol, sucrose and EGTA was
obtained from Boehringer Mannheim Biochemicals (Indianapo-
lis, Indiana, USA), phenylmethylsulfonyichioride (PMSF), dithio-
threitol (Dfl) and EDTA from Sigma Chemicals (St. Louis,
Missouri, USA) and HEPES from JRH Biosciences (Lenexa,
Kansas, USA). Thin layer chromatography plates were from
Whatman (Maidstone, Kentucky, USA). L-3-phosphatidylcholine
1-Stearoyl-2-[1-14C]arachidonyl and ECL system were purchased
from Amersham Corp. (Arlington Heights, Illinois, USA). Acti-
nomycin D, cycloheximide, calphostin, sangivamycin, herbimycin
A and genistein were obtained from Calbiochem (La Jolla,
California, USA), phorbol myristate acetate (PMA) from
GIBCO/BRL (Gaithersburg, Maryland, USA) and heparin from
Lymphomed (Deerfield, Illinois, USA). Polyclonal anti-cPLA2
antibody was a gift from Dr. Joseph V. Bonventre, Harvard
Medical School (Boston, Massachusetts, USA). cPLA2 cDNA was
a gift from Dr. James D. Clark, Genetics Institute, Inc. (Cam-
bridge, Massachusetts, USA).
Results
ET-1 rapidly activates cPLA2 in GMC
Using a direct measurement of enzymatic activity and CHO
cells stably expressing either the human ETA or ETB receptor, we
have recently demonstrated that ET-1 is able to stimulate cPLA2
via both ET-receptor subtypes [281. We now report that ET-1 also
leads to a rapid, time-dependent (Fig. 1A) and dose-dependent
(Fig. 1B) activation of this enzyme in GMC. As shown in Figure
1A, stimulation of GMC cPLA2 by 100 nM ET-1 occurred after
five minutes (146.7 7.87% of control; N = 3),was maximal after
10 minutes (181.8 5.03% of control; N = 8) and persisted up to
40 minutes (174.0 6.69% of control; N = 3). When GMC were
incubated for 10 minutes in the presence of different ET-1
concentrations, maximal activation of cPLA2 occurred at 1O M
ET-1 (183.0 8.96% of control; N = 5; Fig. 1B). Incubation of
cytosolic extracts with 5 mivi Dfl for 10 minutes at room
temperature did not attenuate the ET-1-induced increase in PLA2
activity (data not shown), suggesting that the cytosolic not secre-
tory form of PLA2 is involved in this response. As a positive
control, extracts of GMC were stimulated with 100 n PMA for 20
minutes. In accordance with previous reports [12, 20j, PMA led to
a 241.1 15.40% (N = 4) increase in cPLA2 activity. These
results provide evidence that ET-1 can rapidly activate cPLA2 in
GMC.
Regulation of acute cPLA2 activation by ET-1
To determine the potential mechanisms which could result in
an acute enhancement of cPLA2 activity we next performed both
Northern and Western blot experiments (Fig. 2). As shown in
Figure 2A, 100 nivi ET-1 had no effect on cPLA2 mRNA expres-
sion in GMC during the first 40 minutes. In parallel, ET-1 did not
induce cPLA2 protein expression as shown by immunoblot (Fig.
2B). These results indicate that the rapid stimulation of cPLA2
activity by ET-1 in GMC is most likely due to post-translational
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Fig. 1. Acute time-dependent (A) and dose-dependent (B) stimulation of
cPLA2 activity by ET-1. Confluent rat mesangial cells were treated as
described in section Methods and (A) incubated in the presence or
absence of io M ET-1 at 37°C for the indicated times or (B) incubated
for 10 minutes in the presence of different ET-1 concentrations (10—10 M
to 10 M). Values represent mean sa (% of unstimulated controls) for
number of measurements shown in parenthesis.
modifications of the enzyme rather than to increases in gene
expression and enzyme mass.
In GMC ET-1 is a potent stimulus for both p42 and p44
mitogen-activated protein (MAP) kinase [35], and it was recently
reported by two laboratories that p42 MAP kinase can phosphor-
ylate and activate cPLA2 in vitro [36, 37]. In order to find evidence
for this interaction in intact GMC we investigated the effects of
heparin on ET-1-induced cPLA2 stimulation. Heparin has been
shown to partially inhibit ET-1-induced MAP kinase activation in
GMC [381. Confluent GMC were placed in FBS- and ITS-free
RPMI 1640 for two hours prior to the experiment and then
stimulated for 10 minutes with 100 nivi ET-1, either in the absence
or in the presence of 2 U/ml heparin (2 hr preincubation). When
compared to ET-1 alone (164.1 10.1% of controls; N = 3),
preincubation with heparin for two hours did not alter ET-1-
induced cPLA2 activation (160.6 7.0% of controls; N = 3).
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Fig. 2. Acute effects of ET-1 upon cPLA2 gene
expression (A) and protein formation (B). For
both Northern blot and immunoblot studies
confluent rat mesangial cells were treated as
described in section Methods and incubated in
the presence or absence of iO M ET-1 at
37°C for the indicated times. (A) Northern blot
analysis of 1 of 3 representative time courses.
Hybridization signals were quantified by
scanning densitometry and divided by the fold
increase in GADPH mRNA from the same
blot. Relative cPLA2 mRNA increase is shown
at the bottom of the blot. (B) Western blot
analysis of 1 of 3 representative time courses
using a specific polyclonal cPLA2 antibody.
Incubation of GMC in the presence of heparin alone did not affect synthase-2 (PGHS-2) expression [39] supports a role for PG's to
basal cPLA2 activity (111.3 7.4% of control; N = 3). serve as a long-term autocrine and/or paracrine regulator for
vasoconstrictive and mitogenic actions of ET-1. In the present
ET-l increases expression of cPLA2 rnRNA and protein mass at study we therefore investigated whether or not ET-1 can also
later time points chronically up-regulate cPLA2. One hundred nanomoles of ET-1
Our recent finding that ET-induced release of PGE2 by GMC were added to quiescent GMC for different periods of time and
over 6 to 24 hours is a result of prostaglandin endoperoxide total RNA or total cell lysates were analyzed by Northern or
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Fig. 3. Chronic, time-dependent stimulation of cPLA2 gene expression (A), protein formation (B) and enzymatic activity (C) by ET-1. For both Northern
blot and immunoblot studies as well as for enzymatic activity measurements confluent rat mesangial cells were made quiescent for 24 hours as described
in section Methods and then incubated in the presence or absence of iO- M FT-i at 37°C for the indicated times. (A) Northern blot analysis of 1 of
3 representative time courses. Hybridization signals were quantified by scanning densitometry and divided by the fold increase in GADPH mRNA from
the same blot. Relative cPLA2 mRNA increase is shown at the bottom of the blot. (B) Western blot analysis of 1 of 3 representative time courses using
a specific polyclonal cPLA2 antibody. (C) cPLA2 activity was measured as described in section Methods. Values represent mean SE compared to
unstimulated controls for number of measurements shown in parenthesis.
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Fig. 4. Dose-dependent induction of cPLA2 mRNA by ET-1. Confluent rat
mesangial cells were made quiescent for 24 h as described in section
Methods and then incubated for 6 hours in the presence or absence of
indicated ET-1 concentrations. 1 of 3 representative experiments is shown.
Hybridization signals were quantified by scanning densitometry and
divided by the fold increase in GADPH mRNA from the same blot. cPLA2
mRNA fold increase is shown at the bottom of the blot.
Western blots, respectively. A time-dependent increase in cPLA2
mRNA expression was seen with the earliest increase occurring
within three hours of ET-1 treatment (Fig. 3A). After six hours, a
2 to 2.5-fold increase in steady-state mRNA levels was consis-
tently observed, which was maintained for up to 24 hours. This
ET-1-induced increase in cPLA2 mRNA expression was accom-
panied by an increase in both cPLA2 protein mass (Fig. 3B) and
enzymatic activity (Fig. 3C). While an increase in protein mass
was detected at six hours and was maximal at 12 hours, cPLA2
activity was significantly elevated after six hours (141.6 4.7% of
control; N = 3) and remained increased for up to 24 hours (135.1
2.6% of control; N = 3). These results indicate that cPLA2
mRNA levels can be up-regulated by ET-1 and that this aug-
mented mRNA expression is accompanied by an increase in both
cPLA2 protein mass and enzymatic activity.
ET-1 induced cPLA2 mRNA expression shows dose-dependency
and inhibition by actinomycin D but not by cycloheximide
As shown in Figure 4, ET-1, when incubated for six hours, led
to a dose-dependent increase in cPLA2 mRNA expression with a
threshold at i0 M and a maximal stimulation at i0 M. The
mRNA induction by 100 nrvi ET-1 at six hours was blocked by
actinomycin D (5 tg/ml, 1 hr preincubation), an inhibitor of
transcription (Fig. 5). The translational inhibitor cycloheximide(10 .tg/ml, 1 hr preincubation), on the other hand, increased
cPLA2 mRNA levels in unstimulated control as well as in
ET-1-stimulated GMC (Fig. 5). When administered alone, acti-
1.0 1.9 2.4 2.8 1.1 1.3
Fig. 5. Effects of cycloheximide (CHX) and act inomycin D (Act.D) on
ET-1-induced cPL42 mRNA levels. Incubation of quiescent mesangial cells
was carried out for 6 hours with ET-! (l0- M) alone, CHX (10 j.tg/ml)
alone, CHX (preincubated for 1 hr) plus ET-1, Act.D (5 sWml) alone or
Act.D (preincubated for 1 hr) plus ET-1 and compared to unstimulated
controls. One of 3 representative experiments is shown. Hybridization
signals were quantified by scanning densitometry. cPLA2 mRNA fold
increase is shown at the bottom of the blot.
nomycin D did not affect basal cPLA2 expression. These results
suggest that cPLA2 is present in GMC as an inducible gene.
Furthermore, these data are consistent with the idea that the ET-1
effect is mediated at the transcriptional level.
gene expression
We next examined the role of protein kinase C (PKC) and
protein tyrosine kinases (PTK5) in ET-1-stimulated cPLA2
mRNA accumulation (Fig. 6). To determine whether PKC and/or
PTK mediate induction of cPLA2 mRNA by ET- 1 in GMC, we
evaluated the effects of two PKC inhibitors (caiphostin, sangiva-
mycin) and two PTK inhibitors (herbimycin A, genistein). While
pretreatment of quiescent GMC for one hour with 100 nvi
calphostin only slightly decreased ET-1-stimulated cPLA, mRNA
expression, preincubation with 1 I.tM herbimycin A, a potent
inhibitor of cellular PTKS, completely abolished ET-1-induced
cPLA2 gene expression (Fig. 6). Compared to caiphostin, quali-
tatively similar results were obtained when quiescent GMC were
pretreated for one hour with the PKC inhibitor sangivamycin (100
nM) (Fig. 7). Genistein (6 xWml), a potent inhibitor of ATP
binding site of PTKs, also inhibited cPLA2 mRNA expression by
ET-1 although to a lesser extent than herbimycin A (Fig. 7).
Together these findings indicate that activation of cellular PTKS is
a necessary signaling pathway through which ET-1 stimulates
cPLA2 mRNA expression. An involvement of PKC in ET-1-
regulated cPLA2 mRNA expression, however, cannot be ex-
cluded.
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Fig. 6. Herbinycin A but not caiphostin completely inhibits ET-1 -induced
cPLA2 gene expression. Incubation of quiescent mesangial cells was carried
out for 6 hours with ET-1 (1O M) alone, calphostin (1O- M) alone,
calphostin (1 hr preincubation) plus ET-1, herbimycin A (1O6 M) alone or
herbimycin A (16 hr preincubation) plus ET-1 and compared to unstimu-
lated controls. One of 3 representative experiments is shown. Hybridiza-
tion signals were quantified by scanning densitometry and divided by the
fold increase in GADPH mRNA from the same blot. cPLA2 mRNA fold
increase is shown at the bottom of the blot.
Discussion
We have made parallel evaluations of cPLA2 mRNA expres-
sion, protein formation and enzymatic activity in GMC and have
investigated the acute and chronic regulation of this enzyme by a
U-protein-coupled vasoactive and mitogenic peptide, namely en-
dothelin-l (ET-1). ET-1 rapidly stimulated cPLA2 activity in
GMC which did not require new protein synthesis. This result is in
accordance with previous studies showing that, in glomerular
mesangial cells, cPLA2 can be acutely activated by different
agonists, such as arginine vasopressin (AVP), phorbol myristate
acetate (PMA), epidermal growth factor (EGF) [12, 40}, interleu-
kin-la (IL-la) [20], interleukin-1f3 (IL-113) and transforming
growth factor-2 (TGF-132) [19]. For most of these agonists it has
been reported that the acute increase in cPLA2 activity is due to
a stable post-translational modification of the enzyme [12, 20, 40].
Stimulation of cPLA2 also demonstrates a dependency on intra-
cellular Ca2 that is compatible with physiologic regulation by
Ca2 in intact cells [10]. An agonist-stimulated increase in
intrinsic cPLA2 activity is only apparent when a rise in cytosolic
Ca2 allows translocation of the enzyme to its substrate [10, 12,
16]. However, the catalytic domain of cPLA2 seems to function
independently of the Ca2-dependent lipid-binding domain,
which is necessary for association of cPLA2 with its aggregated
substrate [41]. Although we were not able to detect a band-shift in
immunoblots as an indication for phosphorylation of this enzyme,
it is most likely that phosphorylation is also involved in the rapid
stimulation of cPLA2 by ET-l. Recent in vitro experiments have
indicated that both protein kinase C and MAP kinase can
Fig. 7. Effects of sangivamycin and genistein on ET-1-induced cPLA2 gene
expression. Incubation of quiescent mesangial cells was carried out for 6
hours with ET-1 (10 M) alone, sangivamycin (1O M) alone, sangiva-
mycin (1 hr preincubation) plus ET-1, genistein (6 jg/ml) alone or
genistein (1 hr preincubation) plus ET-1 and compared to unstimulated
controls. One of 3 representative experiments is shown. Hybridization
signals were quantified by scanning densitometry and divided by the fold
increase in GADPH mRNA from the same blot. cPLA2 mRNA fold
increase is shown at the bottom of the blot,
phosphorylate and activate cPLA2 [36, 37]. It has been also
reported that heparin, which has several biological effects includ-
ing inhibition of increments of cytosolic Ca2, reduction of c-fos
[42] and antagonism of cell proliferation [43], can inhibit MAP
kinase in smooth muscle cells [44]. Furthermore, our group has
recently shown that this complex glycosaminoglycan completely
abolished PGE2-induced MAP kinase activity and significantly
inhibited ET-1-induced but not EGF-stimulated MAP kinase
activity in GMC [38]. In the present study we now report that
heparin did not have any effect on ET-l stimulated cPLA2 activity
in intact glomerular mesangial cells. Together with the finding
that PGE2 can stimulate MAP kinase but not cPLA2 activity in
GMC [38] these findings suggest that in intact GMC MAP kinase
is not the only intracellular signal necessary for activation of
cPLA2,
Besides this rapid ET-1-induced stimulation, our chronic incu-
bation experiments reveal that, in addition to the growing list of
cytokine- [20, 29, 30] and growth factor- [31, 32] activated
receptors, G-protein-coupled receptor agonists are able to up-
regulate cPLA2 gene expression as well. The time- and dose-
dependent cPLA2 mRNA expression by ET-1 is accompanied by
protein formation, as assessed by Western analysis, and corre-
sponds to directly measured enzymatic activity suggesting that
newly synthesized GMC cPLA2 is also biologically active. It is
important to note, however, that this chronically stimulated
cPLA2 activity most likely reflects a combination of both post-
translational events as well as an increased abundance of cPLA2
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protein. While the fact that actinomycin D inhibited cPLA2
mRNA accumlation in ET-1-stimulated mesangial cells is consis-
tent with an ET-1 effect mediated at a transcriptional level, a
nuclear run-off analysis would be necessary to definitely confirm
this result. Cycloheximide increased cPLA2 levels in unstimulated
control cells and, when incubated together with ET-1, led to a
2.8-fold increase in cPLA2 mRNA expression. Cycloheximide has
previously been shown to superinduce immediate early-response
genes, including c-fos, c-jun and c-myc by alteration in mRNA
stability in transcripts with AUUUA repeats in 3'-untranslated
regions of the mRNA [45]. Recently, superinduction of EGF-
induced cPLA2 gene expression by cycloheximide has been re-
ported in glomerular mesangial cells [31] and multiple conserved
AUUUA sequences in the 3'-untranslated region of human and
murine cPLA2 have been identified [16]. Besides its possible effect
on cPLA2 mRNA stability, cycloheximide might also inhibit the
translation of transcription factors which normally provide basal
inhibition of cPLA2 gene expression and thereby lead to superin-
duced gene expression.
We also performed experiments to determine the role of
protein kinase C (PKC) and protein tyrosine kinases (PTK) in
ET-1-stimulated cPLA2 gene expression. In comparison to PKC
inhibitors, which only slightly reduced cPLA2 mRNA induction by
ET-1, the cellular PTK inhibitor herbimycin A completely abol-
ished this ET-1 response. These results are in line with recent
studies, which have suggested that vasoconstrictor peptides can
activate both PKC and non-receptor-linked tyrosine kinase activ-
ities [46, 47]. In GMC, PKC was shown to be necessary but not
sufficient for mitogenic signaling by ET-1 [47]. In addition, PTK
activity was required for induction of c-fos, AP-1 DNA binding
activity, and AP-1 cis-element activity by ET-1 [47]. Furthermore,
analysis of the 5' flanking region of the rat cPLA2 gene revealed
multiple potential AP-1 binding sites as well as an NFkB consen-
sus sequence [48]. We thus speculate that ET-1 regulates tran-
scription factors in a PTK-sensitive way, and that this might be
one mechanism by which ET-1 activates cPLA2 mRNA expres-
sion. Alternatively, a tyrosine kinase may regulate phosphoryla-
tion of a cytoplasmic protein which binds to the 3' untranslated
region and stabilizes cPLA2 mRNA.
Together these results are consistent with the idea that ET-1
regulates cPLA2 both acutely as well chronically. This biphasic
stimulation most likely involves different mechanisms, the rapid
cPLA2 activation being mainly post-translationally regulated,
while the chronic cPLA2 stimulation also occurring at a transcrip-
tional level. In support of earlier reports [1, 3, 4, 9, 24, 28, 39], we
suggest that ET-1-induced short-term and long-term activation of
cPLA2 plays an important role in the ET-1-mediated release of
PGs and thereby may serve as an autocrine and/or paracrine
negative regulator for vasoconstrictive, mitogenic and inflamma-
tory stimuli. Moreover, these results are in line with our recent
experiments showing that ET-1 induces prostaglandin endoper-
oxide synthase-2 (PGHS-2) mRNA expression, protein formation
and bioactivity [39], thereby enhancing cellular capacity not only
to release arachidonic acid but also to convert arachidonate to
biologically active PGs such as PGE2.
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